Cellectis (ALCLS) investor relations material

Executive summary

• Received FDA RMAT designation for lasme-cel in r/r B-ALL, reflecting promising efficacy and manageable safety profile in pivotal Phase 2 BALLI-01 trial.

• Presented full Phase 1 data for lasme-cel and translational data for eti-cel at EHA 2026, with further interim and full datasets expected in Q4 2026.

• Cash, cash equivalents, and fixed-term deposits totaled $169 million as of June 30, 2026, providing runway into Q4 2027.

Financial highlights

• Revenues and other income for H1 2026 were $14.5 million, down from $30.2 million in H1 2025, mainly due to lower activity under the AstraZeneca collaboration.

• R&D expenses increased to $52.2 million in H1 2026 from $45.0 million in H1 2025, driven by higher personnel and clinical development costs.

• SG&A expenses rose to $11.3 million in H1 2026 from $9.8 million in H1 2025, mainly due to increased stock-based compensation.

• Net financial gain of $9.2 million in H1 2026, compared to a $18.1 million loss in H1 2025, due to fair value gains and reduced FX losses.

• Net loss attributable to shareholders was $39.6 million ($0.39/share) in H1 2026, slightly improved from $41.9 million ($0.42/share) in H1 2025.

• Adjusted net loss was $35.6 million ($0.35/share) in H1 2026, compared to $39.6 million ($0.40/share) in H1 2025.

Outlook and guidance

• Pivotal Phase 2 BALLI-01 interim analysis expected in Q4 2026; full Phase 1 dataset for NATHALI-01 also anticipated in Q4 2026.

• Cash runway expected to fund operations into Q4 2027, with focus on advancing clinical pipeline and manufacturing capabilities.